Cargando…
Low tumour-infiltrating lymphocyte density in primary and recurrent glioblastoma
Immunotherapies targeting tumour-infiltrating lymphocytes (TILs) that express the immune checkpoint molecule programmed cell death-1 (PD-1) have shown promise in preclinical glioblastoma models but have had limited success in clinical trials. To assess when glioblastoma is most likely to benefit fro...
Autores principales: | Maddison, Kelsey, Graves, Moira C., Bowden, Nikola A., Fay, Michael, Vilain, Ricardo E., Faulkner, Sam, Tooney, Paul A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522837/ https://www.ncbi.nlm.nih.gov/pubmed/34676050 http://dx.doi.org/10.18632/oncotarget.28069 |
Ejemplares similares
-
Vasculogenic Mimicry Occurs at Low Levels in Primary and Recurrent Glioblastoma
por: Maddison, Kelsey, et al.
Publicado: (2023) -
Characteristics of vasculogenic mimicry and tumour to endothelial transdifferentiation in human glioblastoma: a systematic review
por: Maddison, Kelsey, et al.
Publicado: (2023) -
Transcriptomic Profiling of DNA Damage Response in Patient-Derived Glioblastoma Cells before and after Radiation and Temozolomide Treatment
por: Lozinski, Mathew, et al.
Publicado: (2022) -
Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma
por: Naghavian, Reza, et al.
Publicado: (2023) -
Pilot early phase II study of decitabine and carboplatin in patients with advanced melanoma
por: van der Westhuizen, Andre, et al.
Publicado: (2020)